7,904 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Bought by Sapient Capital LLC

Sapient Capital LLC purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The fund purchased 7,904 shares of the company's stock, valued at approximately $1,241,000.

Other hedge funds have also added to or reduced their stakes in the company. Fidelis Capital Partners LLC bought a new position in shares of TransMedics Group in the first quarter valued at approximately $35,000. International Assets Investment Management LLC purchased a new position in TransMedics Group in the second quarter valued at about $47,000. USA Financial Formulas bought a new position in shares of TransMedics Group during the 3rd quarter valued at approximately $55,000. J.Safra Asset Management Corp increased its stake in shares of TransMedics Group by 649.2% during the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company's stock worth $67,000 after purchasing an additional 383 shares during the last quarter. Finally, Signaturefd LLC raised its holdings in shares of TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company's stock worth $67,000 after purchasing an additional 93 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on TMDX. Oppenheimer raised their target price on TransMedics Group from $125.00 to $200.00 and gave the stock an "outperform" rating in a research report on Thursday, August 1st. Robert W. Baird assumed coverage on TransMedics Group in a research note on Tuesday, September 24th. They issued an "outperform" rating and a $200.00 price objective on the stock. Morgan Stanley increased their target price on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an "equal weight" rating in a research report on Monday, July 15th. Piper Sandler reissued an "overweight" rating and issued a $180.00 price target on shares of TransMedics Group in a research report on Monday, October 7th. Finally, Needham & Company LLC initiated coverage on shares of TransMedics Group in a report on Wednesday, August 21st. They issued a "buy" rating and a $208.00 price objective for the company. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $174.30.

Insider Buying and Selling

In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total transaction of $438,493.92. Following the completion of the sale, the insider now owns 20,843 shares of the company's stock, valued at $3,089,766.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the business's stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $149.96, for a total value of $1,012,230.00. Following the completion of the sale, the director now directly owns 732 shares of the company's stock, valued at $109,770.72. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Tamer I. Khayal sold 2,958 shares of the company's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the sale, the insider now owns 20,843 shares of the company's stock, valued at approximately $3,089,766.32. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 55,580 shares of company stock worth $8,837,283. Corporate insiders own 7.00% of the company's stock.

TransMedics Group Price Performance

TransMedics Group stock traded down $2.40 during midday trading on Tuesday, hitting $131.84. 730,560 shares of the company's stock were exchanged, compared to its average volume of 830,649. The stock has a 50-day moving average price of $154.92 and a two-hundred day moving average price of $137.20. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $177.37. The company has a market cap of $4.34 billion, a P/E ratio of -394.81 and a beta of 1.99. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company had revenue of $114.30 million for the quarter, compared to analysts' expectations of $98.84 million. During the same period in the prior year, the business earned ($0.03) earnings per share. TransMedics Group's revenue for the quarter was up 117.7% compared to the same quarter last year. On average, equities research analysts forecast that TransMedics Group, Inc. will post 1.22 earnings per share for the current year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.